TROV vs. EDIT, MOLN, AGEN, CGEN, ACOG, KYTX, LXEO, IKT, ALEC, and BDTX
Should you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Editas Medicine (EDIT), Molecular Partners (MOLN), Agenus (AGEN), Compugen (CGEN), Alpha Cognition (ACOG), Kyverna Therapeutics (KYTX), Lexeo Therapeutics (LXEO), Inhibikase Therapeutics (IKT), Alector (ALEC), and Black Diamond Therapeutics (BDTX). These companies are all part of the "medical" sector.
Cardiff Oncology vs. Its Competitors
Cardiff Oncology (NASDAQ:TROV) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk, institutional ownership and community ranking.
Editas Medicine has a consensus price target of $5.36, suggesting a potential upside of 172.27%. Given Editas Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Editas Medicine is more favorable than Cardiff Oncology.
In the previous week, Editas Medicine had 10 more articles in the media than Cardiff Oncology. MarketBeat recorded 10 mentions for Editas Medicine and 0 mentions for Cardiff Oncology. Editas Medicine's average media sentiment score of 1.02 beat Cardiff Oncology's score of 0.00 indicating that Editas Medicine is being referred to more favorably in the news media.
Editas Medicine has a net margin of -340.96% compared to Cardiff Oncology's net margin of -3,688.31%. Editas Medicine's return on equity of -80.13% beat Cardiff Oncology's return on equity.
10.0% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 0.6% of Cardiff Oncology shares are owned by company insiders. Comparatively, 2.1% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Cardiff Oncology received 85 more outperform votes than Editas Medicine when rated by MarketBeat users. Likewise, 73.09% of users gave Cardiff Oncology an outperform vote while only 53.46% of users gave Editas Medicine an outperform vote.
Cardiff Oncology has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.1, meaning that its share price is 110% more volatile than the S&P 500.
Cardiff Oncology has higher earnings, but lower revenue than Editas Medicine. Cardiff Oncology is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.
Summary
Editas Medicine beats Cardiff Oncology on 14 of the 19 factors compared between the two stocks.
Get Cardiff Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TROV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiff Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:TROV) was last updated on 6/13/2025 by MarketBeat.com Staff
Buy TROV Stock Free TROV Stock Alerts